UnitedHealth Optum Rx PreCheck AI Cuts Prior Authorization Time to Under 30 Seconds

Optum Rx PreCheck Prior Authorization is an AI tool that automates the submission and approval of prior authorizations for prescription drugs by retrieving clinical data from providers' electronic medical records.

Executive Summary

UnitedHealth Group operates Optum Rx as its pharmacy benefits manager and has deployed the PreCheck Prior Authorization tool across its healthcare operations. The AI system addresses longstanding delays in prescription approvals by automatically accessing patient data from electronic medical records. This deployment targets a specific administrative process that has historically required manual review by physicians, pharmacists, and staff.

The company developed PreCheck in partnership with Surescripts and conducted a pilot at Cleveland Clinic along with another large health system. The tool is now available for more than 25 medications, including GLP-1 agonists used for diabetes management as well as drugs for ADHD, irritable bowel syndrome, asthma, and dry eyes. UnitedHealth has referenced the initiative in its Q1 2026 earnings call as part of a $1.5 billion annual investment in artificial intelligence capabilities.

Key quantified outcomes include a reduction in median processing time from 8.5 hours to under 30 seconds, a 68 percent drop in denials due to missing information, and an 88 percent decrease in appeals. Sixty-two percent of approvals for medications within the tool's scope are now handled automatically, while 25 percent of applicable requests receive instant approval without further review.

Background and Context

Prior authorization requirements in prescription drug coverage create administrative workloads for healthcare providers and payers alike. These processes traditionally involve submission of clinical documentation followed by manual verification, which can extend decision timelines to multiple hours or days. UnitedHealth Group, as one of the largest integrated health services companies, manages significant volumes of such requests through its Optum Rx division.

The administrative burden associated with prior authorizations has been documented as a source of delays in patient care and increased operational costs for both providers and payers. UnitedHealth has positioned artificial intelligence investments to target these inefficiencies within its pharmacy benefits operations. The PreCheck tool represents one concrete application within a larger portfolio of technology initiatives.

Industry observers have noted that automated decision systems in healthcare face increasing regulatory and public scrutiny regarding accuracy and transparency. UnitedHealth's approach integrates data retrieval directly from existing electronic medical record systems rather than requiring new data entry from clinical staff. This design choice aims to minimize additional workflow disruption while accelerating approvals.

The scale of UnitedHealth's operations provides a substantial test environment for the PreCheck system. The company processes large numbers of prior authorization requests annually across its network of members and providers. Successful automation at this volume demonstrates measurable operational impact beyond smaller-scale pilots.

Partnership and Pilot Implementation

Optum Rx developed the PreCheck tool through a partnership with Surescripts, a company that facilitates electronic prescribing and related data exchange. The collaboration enabled direct access to clinical information stored in provider electronic medical records without requiring separate submissions from physicians or pharmacists. This integration forms the core mechanism for automation.

Initial testing occurred through a pilot program involving Cleveland Clinic and one additional large health system. Cleveland Clinic associate chief medical information officer Dr. Eric Boose participated in the evaluation and provided direct feedback on the system's performance. The pilot phase validated the tool's ability to handle real-world clinical data across multiple medication categories.

Following the pilot, UnitedHealth expanded availability to more than 25 specific drugs. The selection includes high-volume categories such as GLP-1 receptor agonists prescribed for diabetes as well as medications for ADHD, IBS, asthma, and dry eyes. Expansion decisions appear tied to the volume of prior authorization requests and the availability of structured clinical data in electronic records.

Technical Specifics of PreCheck AI

The PreCheck system operates by querying electronic medical records for required clinical criteria when a prior authorization request is initiated. It retrieves relevant patient data such as diagnoses, lab results, and prior treatment history that support or refute approval criteria. This retrieval occurs automatically through established data exchange protocols managed by Surescripts.

Once data is retrieved, the AI applies predefined rules to determine whether the request meets coverage criteria. Approved requests proceed without human intervention, while others are flagged for review. The system currently handles 62 percent of approvals for in-scope medications through this automated pathway, with 25 percent of requests receiving immediate approval.

The technical architecture avoids requiring additional data entry from clinical staff, which distinguishes it from earlier electronic prior authorization attempts. By leveraging data already present in the chart, the tool reduces the risk of incomplete submissions that historically led to denials. This approach directly addresses the 68 percent reduction in denials attributed to missing information.

UnitedHealth has indicated that the system integrates with existing provider workflows rather than introducing new portals or interfaces. This design choice supports broader adoption across health systems that already maintain electronic medical records. The current scope remains limited to specific medications where clinical criteria are well-defined and data elements are consistently captured.

Quantified Business Outcomes

The primary outcome metric is the reduction in median turnaround time from 8.5 hours to under 30 seconds, with a reported median of 29 seconds. This change applies to requests processed through the PreCheck pathway. The time savings eliminate the multi-hour delays that previously characterized manual review cycles.

Secondary outcomes include an 88 percent reduction in appeals and a 68 percent reduction in denials caused by insufficient information. These figures are drawn from data reported by Surescripts following the pilot and initial rollout. Lower appeal volumes reduce administrative workload for both the payer and provider organizations.

Automation rates show that 62 percent of approvals for medications within scope are now handled by the AI system. An additional 25 percent of applicable requests receive automatic approval upon submission. These percentages reflect current performance levels and indicate the proportion of requests that no longer require manual intervention.

Prior Authorization Performance Metrics Before and After PreCheck Deployment

Metric	Before Implementation	After Implementation
Median Approval Time	8.5 hours	Under 30 seconds (median 29 seconds)
Denials Due to Missing Information	Baseline	68% reduction
Appeals Volume	Baseline	88% reduction
Automated Approvals (in-scope)	Not applicable	62% of approvals
Instant Approvals	Not applicable	25% of applicable requests

Market and Stakeholder Implications

For other healthcare payers and pharmacy benefit managers, the PreCheck results provide a benchmark for AI-driven automation of administrative processes. The quantified reductions in time, denials, and appeals demonstrate concrete operational efficiency gains that can be measured against existing workflows. Executives evaluating similar tools can reference the specific percentages achieved in a large-scale deployment.

Providers participating in the pilot, including Cleveland Clinic, experienced reduced administrative burden because the system pulls data directly from existing records. This approach eliminates the need for staff to compile and submit documentation for each request. The reported feedback from Dr. Eric Boose highlights the practical benefit of automation without additional physician or pharmacist effort.

Patients may experience faster access to prescribed medications when approvals occur in seconds rather than hours. The reduction in appeals also suggests fewer instances where coverage decisions are contested, which can shorten the overall time from prescription to fulfillment. These effects align with UnitedHealth's stated goal of easing interactions for clients, members, and providers.

The initiative forms part of UnitedHealth Group's reported $1.5 billion annual investment in artificial intelligence. This broader spending context indicates that PreCheck represents one component within a larger technology strategy rather than an isolated project. Other payers considering comparable investments can assess the return through the reported metrics on time and denial reductions.

Expert Reactions and Commentary

Dr. Eric Boose, associate chief medical information officer at Cleveland Clinic, provided direct commentary on the system's performance during the pilot phase. His observations focus on the elimination of manual data collection steps and the resulting reduction in staff workload. The feedback underscores the value of leveraging data already present in clinical systems.

It is amazing to take what is already there in the chart to automate prior authorization without any effort from the physician, pharmacist or staff. I feel the promise and excitement of automation actually happening and working, and hope it grows quickly.Dr. Eric Boose, associate chief medical information officer, Cleveland Clinic

Optum CEO Patrick Conway has referenced the PreCheck tool in the context of UnitedHealth's overall AI strategy. His comments emphasize the objective of easing interactions for clients, members, and providers through improved process efficiency. This executive perspective situates the specific tool within the company's larger technology and operational priorities.

What's Next for AI in Healthcare Administration

UnitedHealth has indicated continued expansion of the PreCheck tool to additional medications where clinical criteria can be reliably extracted from electronic records. The current coverage of more than 25 drugs provides a foundation for identifying further opportunities based on request volume and data availability.

The reported success metrics may inform decisions by other health systems and payers evaluating similar automation projects. The partnership model with Surescripts offers one example of how data exchange capabilities can support AI applications without requiring new infrastructure from providers.

Ongoing monitoring of denial and appeal rates will determine whether the initial reductions are sustained as the system scales. The 68 percent and 88 percent improvements provide baseline figures against which future performance can be compared. UnitedHealth's reference to the tool in earnings materials suggests continued internal tracking of these operational indicators.

Executive Takeaways

C-suite leaders evaluating AI applications in healthcare administration can draw several practical lessons from the PreCheck deployment. The following ordered list summarizes actions that peer executives may consider when assessing comparable initiatives.

1. Identify administrative processes with high manual review volumes and measurable denial or appeal rates as initial targets for automation.
2. Prioritize AI tools that integrate directly with existing electronic medical record systems to avoid additional data entry requirements.
3. Establish clear baseline metrics for turnaround time, denial rates, and appeal volumes before implementation to enable accurate before-and-after comparison.
4. Conduct limited pilots with partner health systems to validate performance on real clinical data prior to broader rollout.
5. Track automation percentages and instant approval rates as leading indicators of operational impact beyond time savings alone.

Frequently Asked Questions

The following section addresses common questions from enterprise decision makers regarding the PreCheck implementation and its applicability to other organizations.

What specific medications are currently supported by the PreCheck tool?

The tool is currently available for more than 25 drugs including GLP-1s for diabetes, ADHD medications, and treatments for IBS, asthma, and dry eyes. Expansion decisions are based on the volume of prior authorization requests and the availability of structured clinical data in electronic records.